Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer

Next Previous
X
Search
Trial Profile

Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niraparib (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-162; TOPACIO
  • Sponsors TESARO

    • Most Recent Events

    • 08 Oct 2021 Status changed from active, no longer recruiting to completed.
    • 08 Sep 2021 Planned End Date changed from 21 Jul 2021 to 17 Sep 2021.
    • 18 May 2021 Planned End Date changed from 30 Apr 2021 to 21 Jul 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top